European Companies Search Engine
EU funding (€4,009,373): anti-Bacterial Innovative Vaccine Training Network. Hor28 Aug 2019 EU Research and Innovation programme "Horizon"
Overview
Text
anti-Bacterial Innovative Vaccine Training Network.
BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative mindsets. BactiVax will train ESRs in a broad range of transferable skills enabling them to thrive in careers in vaccine research within academia and/or industry through discovery, development, and delivery of innovative therapeutic and prophylactic vaccines. The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to: 1) Identify novel, protective vaccine antigens against target pathogens; 2) Optimise the host response to vaccines; 3) Optimise vaccine delivery; 4) Lead on vaccine advocacy. BactiVax includes 2 SME beneficiaries, a multinational vaccine company and 4 SMEs as partners all of whom are involved in training, entrepreneurship, commercial vaccine development and vaccine antigen processing. All ESRs will have secondments in non-academic environment to enhance their exposure to the commercial. Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines
Funded Companies:
| Company name | Funding amount |
| Asociacion Centro de Investigacion CRL en Biociencias | €501,810 |
| Consiglio Nazionale Delle Ricerche | €261,500 |
| ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | €281,277 |
| Eotvos Lorand Tudomanyegyetem | €229,715 |
| Immunxperts | €256,320 |
| Imperial College of Science Technology and Medicine | €303,173 |
| LIONEX GmbH | €252,788 |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | €505,577 |
| St George's Hospital Medical School | €303,173 |
| The Queen's University of Belfast | €303,173 |
| Universita' Degli Studi Di Milano-Bicocca | €261,500 |
| University College Dublin, National University of Ireland, Dublin | €549,369 |
Source: https://cordis.europa.eu/project/id/860325
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Asociacion Centro de Investigacion CRL en Biociencias - EU funding (€4,009,373): anti-Bacterial Innovative Vaccine Training Network."
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
